Literature DB >> 9261362

Mapping promoter regions that are hypersensitive to methylation-mediated inhibition of transcription: application of the methylation cassette assay to the Epstein-Barr virus major latency promoter.

K D Robertson1, R F Ambinder.   

Abstract

Methylation-associated transcriptional repression is recognized in many settings and may play a role in normal differentiation and in tumorigenesis. Both sequence-specific and nonspecific mechanisms have been elaborated. Recently, we have presented evidence that methylation-associated inhibition of the Epstein-Barr virus (EBV) major latency promoter (BamHI C promoter or Cp) in Burkitt's lymphoma and Hodgkin's disease may play an important role in the pathogenesis of these tumors by protecting them from CD8+ cytotoxic T-cell immunosurveillance. The mechanism of transcriptional repression may relate to specific inhibition of the binding of a cellular transcription factor by methylation. To dissect the viral promoter with regard to transcriptional sensitivity to methylation, we have devised an assay that allows the methylation of discrete regions of reporter plasmids. During the course of the assay, methylation patterns appeared to be stable; there was no evidence of either spread or reversal of the imposed methylation pattern. Application of the assay to the 3.8-kb region upstream of the major EBV latency promoter with natural Cp reporter plasmids showed that sensitivity to methylation is not homogeneously distributed but is concentrated in two discrete regions. The first of these methylation-hypersensitive regions (MHRI) is the previously identified EBNA-2 response element, which includes the methylation-sensitive CBF2 binding site. The second (MHRII) is a sequence further downstream whose potential role in methylation-mediated transcriptional repression had been previously unsuspected. In chimeric enhancer/promoter plasmids, methylation of this downstream region was sufficient to virtually abolish simian virus 40 enhancer-driven transcription. Further dissection indicated that methylation of the EBNA-2 response element (MHRI) was sufficient to abolish EBNA-2-mediated Cp activity while methylation of a region including the EBNA-2 response element and downstream sequence (MHRI and MHRII) was sufficient to abolish all Cp-mediated reporter activity, including that driven by the EBNA-1-dependent enhancer in the origin of plasmid replication, oriP.

Entities:  

Mesh:

Year:  1997        PMID: 9261362      PMCID: PMC191918     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines.

Authors:  M T Puglielli; M Woisetschlaeger; S H Speck
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

2.  Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA.

Authors:  L Waltzer; M Perricaudet; A Sergeant; E Manet
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

3.  trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1.

Authors:  D Reisman; B Sugden
Journal:  Mol Cell Biol       Date:  1986-11       Impact factor: 4.272

4.  CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.

Authors:  K D Robertson; A Manns; L J Swinnen; J C Zong; M L Gulley; R F Ambinder
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

5.  Effect of regional DNA methylation on gene expression.

Authors:  I Keshet; J Yisraeli; H Cedar
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

6.  Molecular genetic analysis of Epstein-Barr virus Cp promoter function.

Authors:  T J Evans; P J Farrell; S Swaminathan
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

7.  Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region.

Authors:  D R Rawlins; G Milman; S D Hayward; G S Hayward
Journal:  Cell       Date:  1985-10       Impact factor: 41.582

8.  Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial.

Authors:  K D Robertson; S D Hayward; P D Ling; D Samid; R F Ambinder
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

9.  Characterization of Epstein-Barr virus recombinants with deletions of the BamHI C promoter.

Authors:  S Swaminathan
Journal:  Virology       Date:  1996-03-15       Impact factor: 3.616

10.  A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1.

Authors:  F Chen; J Z Zou; L di Renzo; G Winberg; L F Hu; E Klein; G Klein; I Ernberg
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  18 in total

1.  Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis.

Authors:  Q Tao; L J Swinnen; J Yang; G Srivastava; K D Robertson; R F Ambinder
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus.

Authors:  D Salamon; M Takacs; D Ujvari; J Uhlig; H Wolf; J Minarovits; H H Niller
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator.

Authors:  J Chen; K Ueda; S Sakakibara; T Okuno; C Parravicini; M Corbellino; K Yamanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

4.  The nucleotide polymorphisms within the Epstein-Barr virus C and Q promoters from nasopharyngeal carcinoma affect transcriptional activity in vitro.

Authors:  Feng-Wei Wang; Xian-Rui Wu; Wen-Ju Liu; Ying-Jie Liang; Yu-Fan Huang; Yi-Ji Liao; Chun-Kui Shao; Yong-Sheng Zong; Shi-Juan Mai; Dan Xie
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-12-07       Impact factor: 2.503

5.  Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency.

Authors:  David J Hughes; Elessa M Marendy; Carol A Dickerson; Kristen D Yetming; Clare E Sample; Jeffery T Sample
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

6.  The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive.

Authors:  Q Tao; K D Robertson; A Manns; A Hildesheim; R F Ambinder
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

7.  The role of promoter methylation in Epstein-Barr virus (EBV) microRNA expression in EBV-infected B cell lines.

Authors:  Do Nyun Kim; Yoon Jae Song; Suk Kyeong Lee
Journal:  Exp Mol Med       Date:  2011-07-30       Impact factor: 8.718

8.  trans-Repression of protein expression dependent on the Epstein-Barr virus promoter Wp during latency.

Authors:  David J Hughes; Carol A Dickerson; Marie S Shaner; Clare E Sample; Jeffery T Sample
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

9.  Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation.

Authors:  E M Fuentes-Pananá; P D Ling
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

10.  High-resolution methylation analysis and in vivo protein-DNA binding at the promoter of the viral oncogene LMP2A in B cell lines carrying latent Epstein-Barr virus genomes.

Authors:  Daniel Salamon; Maria Takacs; Fritz Schwarzmann; Hans Wolf; Janos Minarovits; Hans Helmut Niller
Journal:  Virus Genes       Date:  2003-08       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.